Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - bernard+beall
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Diagnostic Antigens for the Identification of Latent Tuberculosis Infection
CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits M. tuberculosis secreted latency specific antigens, such as alpha-crystallin, in the blood or urine...
Published: 10/28/2024
|
Inventor(s):
Manon Deslauriers
,
Kristin Birkness
,
Peter King
,
Bernard Beall
,
Frederick Quinn
Keywords(s):
ANTIGENS
,
CDC Docket Import
,
CDC Docket Import CDC Prosecuting
,
DA3XXX
,
DAXXXX
,
DC4XXX
,
DCXXXX
,
DDXXXX
,
DEXXXX
,
diagnostic
,
DXXXXX
,
Granuloma
,
Human
,
IA3XXX
,
Identification
,
Latent
,
Methods
,
Model
,
OID-NCHHSTP-DTE
,
TUBERCULOSIS
,
VAXXXX
,
Vitro
,
VJXXXX
,
WBXXXX
,
WFXXXX
,
WIXXXX
,
XAXXXX
,
XCXXXX
,
YBXXXX
,
YDXXXX
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Geriatrics
,
TherapeuticArea > Immunology
,
Application > Consumer Products
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
,
Application > Diagnostics
,
ResearchProducts > Antibodies
,
Application > Vaccines
,
Application > Occupational Safety and Health
Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy
CDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and...
Published: 10/28/2024
|
Inventor(s):
Manon Deslauriers
,
Kristin Birkness
,
Peter King
,
Bernard Beall
,
Frederick Quinn
Keywords(s):
AC4XXX
,
AC5XXX
,
ACXXXX
,
ANTIGENS
,
AXXXXX
,
CDC Docket Import
,
CDC Docket Import CDC Prosecuting
,
DA3XXX
,
DAXXXX
,
DC4XXX
,
DCXXXX
,
DDXXXX
,
DEXXXX
,
diagnostic
,
DXXXXX
,
Granuloma
,
Human
,
IA3XXX
,
Identification
,
Latent
,
Methods
,
Model
,
OID-NCHHSTP-DTE
,
TUBERCULOSIS
,
Vitro
,
VJXXXX
,
WBXXXX
,
WFXXXX
,
WIXXXX
,
WMXXXX
,
XHXXXX
,
YBXXXX
,
YFXXXX
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Infectious Disease
,
Application > Vaccines
,
Application > Consumer Products
,
Application > Occupational Safety and Health
,
ResearchProducts > Research Equipment
,
TherapeuticArea > Immunology
,
Application > Research Materials
,
Application > Diagnostics
Peptide Vaccines Against Group A Streptococci
This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional...
Published: 10/28/2024
|
Inventor(s):
George Carlone
,
Jacquelyn Sampson
,
Edwin Ades
,
Bernard Beall
Keywords(s):
Against
,
CDC Docket Import
,
CDC Docket Import CDC Prosecuting
,
DA3XXX
,
DAXXXX
,
DB3XXX
,
DBXXXX
,
DC4XXX
,
DCXXXX
,
GROUP
,
OID-NCIRD-DBD
,
Peptide
,
Streptococci
,
vaccines
Category(s):
Collaboration Sought > Licensing
,
Application > Diagnostics
,
Application > Therapeutics
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease